Carvedilol and Pycnogenol^® improve the function of diabetic hearts in rats

[1] Antelava N, Gabunia L, Gambashidze K, Petriashvili Sh, Bejitashvili N: Effect of carvedilol, lozartan and trimetazidin on functional parameters of isolated heart of rats at oxidative stress. Georgian Med News. 2009; 2 (167): 81-84.Search in Google Scholar

[2] Battiprolu PK, Gillette TG, Wang ZV, Lavandero S, Hill JA: Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets. Drug Discov Today Dis Mech. 2010; 7 (2): 135-143.10.1016/j.ddmec.2010.08.001Search in Google Scholar

[3] Bauters C, Lamblin N, Mc Fadden EP, Van Belle E, Millaire A, de Groote P. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovas Diabetol. 2003; 2 (1):1-16.10.1186/1475-2840-2-1Search in Google Scholar

[4] Drobna V, Drafi F, Jankyova S: Vplyv polyfenolov na kardiovaskularne poškodenie pri diabetus mellitus. Pokroky vo farmakologii v Slovenskej republike VI, FaF UK 2011; 15-21.Search in Google Scholar

[5] El-Sherif N, Turitto G: Electrophysiologic Effects of Carvedilol: Is Carvedilol an Antiarrhythmic Agent? Pace. 2005; 28: 985-990.10.1111/j.1540-8159.2005.00200.xSearch in Google Scholar

[6] Emre M, Kavak S, Unlugenc H: The effects of telmisartan on mechanical responses of left ventricular papillary muscle in rats with streptozotocin-induced diabetes mellitus. Acta Diabetol. 2010; 47 (1 suppl):153-159.10.1007/s00592-009-0156-xSearch in Google Scholar

[7] Grimm D, Jabusch H, Kossmehl P, Huber M, Fredersdorf S, Griese DP, Kramer BK, Kromer EP: Experimental diabetes and left ventricular hypertrophy. Effects of beta-receptor blockade. Cardiovas Pathology.2002;11: 229-237.10.1016/S1054-8807(01)00116-8Search in Google Scholar

[8] Goyal BR, Parmar K, Goyal RK, Mehta AA: Beneficial role of telmisartan on cardiovascularcomplications associated with STZ-induced type 2 diabetes in rats. Pharmacol Report. 2011; 63: 956-966.10.1016/S1734-1140(11)70611-9Search in Google Scholar

[9] Hosseini S, Lee J, Sepulveda RT, Rohdewald P, Watson RR: A randomized, double-blind, placebo-controlled, prospective, 16 week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutr Res. 2001; 21: 1251-1260.10.1016/S0271-5317(01)00342-6Search in Google Scholar

[10] Huang H, Shan J, Pan X, Wang H, Qian L: Carvedilol protected diabetic rat hearts via reducing oxidative stress. J Zhejiang Univ SCIENCE B. 2006; 7 (9): 725-731.10.1631/jzus.2006.B0725155979316909474Search in Google Scholar

[11] Huang H , Shan J, Pan XH , Wang HP , Qian LB, Xia Q: Carvedilol improved diabetic rat cardiac function depending on antioxidant ability. Diabetes Research and Clinical Practice. 2007; 75: 7-13.10.1016/j.diabres.2006.04.01616780994Search in Google Scholar

[12] Izraelova, J et.al.:Normalizacia korekcie intervalu QT u potkanov. Zbornik prac, 56. Farmakologicke dni, Bratislava. 2006:149.Search in Google Scholar

[13] Jankyova S, Kucera P, Goldenberg Z, Yaghi D, Navarova J, Kyselova Z, Stolc S, Klimas J, Racanska E, Matyas S : Pycnogenol R Efficiency on Glycaemia, Motor Nerve Conduction Velocity and Markers of Oxidative Stress in Mild Type Diabetes in Rats. Phytother. Res. 2009; 23: 1169-1174.Search in Google Scholar

[14] Jankyova S, Kmecova J, Cernecka H, Mesarosova L, Musil P, Brnoliakova Z, Kyselovic J, Babal P, Klimas J: Glucose and blood pressure lowering effects of PycnogenolR are inefficient to prevent prolongation of QT interval in experimental diabetic cardiomyopathy. Pathology - Research and Practice. 2012; 208: 452-457.10.1016/j.prp.2012.05.01022749577Search in Google Scholar

[15] Jankyova S, Hlavackova L, Kralova E, Slazneva J, Drobna V, Zuzik P, Drafi F., Mucaji P, Racanska E: The evaluation of efficacy of PycnogenolR fractions on endothelial dysfunction. Acta Fac. Pharm. Univ. Comen., 2013; LX: (1), 7-14.10.2478/afpuc-2013-0014Search in Google Scholar

[16] Kinsel JF, Straus SE: Complementary and alternative therpaeutics: rigorous research is needed to support claims. In Annual review of pharmacology and toxicology. 2003; 43: 463-484.10.1146/annurev.pharmtox.43.100901.135757Search in Google Scholar

[17] Kitabchi AE, Wall BM: Diabetic ketoacidosis. Med Clin North Am. 1995;79: 9-37.10.1016/S0025-7125(16)30082-7Search in Google Scholar

[18] Klimas J, Kmecova J, Jankyova S, Yaghi D, Priesolova E., Kyselova Z, Musil P, Ochodnicky P, Krenek P, Kyselovic J, Matyas S: PycnogenolR Improves Left Ventricular Function in Streptozotocin-Induced Diabetic Cardiomyopathy in Rats.Phytother Res. 2010; 24: 969-974.10.1002/ptr.3015Search in Google Scholar

[19] Kuželova M: Principy farmakologie kardiovaskularneho systemu pre farmaceutov, vydavateľstvo SAV;Bratislava 2008, 35.Search in Google Scholar

[20] Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BV, Welty TK, Lee ET, Devereux RB: The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Car 2001; 37:1943-1949.10.1016/S0735-1097(01)01230-XSearch in Google Scholar

[21] Maimoona A, Naeem I, Saddiqe Z, Jameel K: Review on biological, nutraceutical and clinical aspects of french maritime pine bark. Journal of Ethnopharmacology. 2010; 133(2): 1-53.10.1016/j.jep.2010.10.041Search in Google Scholar

[22] Miller JA, Floras JS, Zinman B, Skorecki KL, Logan AG: Effect of hyperglycemia on arterial pressure, plasma renin activity, and renal function in early diabetes. Clin Sci. 1996; 90:189-195.10.1042/cs0900189Search in Google Scholar

[23] Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334(21):1349-55.10.1056/NEJM199605233342101Search in Google Scholar

[24] Packer G, Rimbach F, Virgili R: Antioxidant activity and biologic properties of procyanidin-rich extract from pine (Pinus maritime) bark, Pycnogenol. Free Radical Biol Med.1999; 27: 704-724.10.1016/S0891-5849(99)00090-8Search in Google Scholar

[25] Ruffolo RR, Bril A, Feuerstein GZ: Cardioprotective potential of carvedilol. Cardiology. 1993;82:24-8.10.1159/0001759308106160Search in Google Scholar

[26] Spindler M, Saupe KW, Tian R, Ahmed S, Mohammed A, Ingwall JS: Altered Creatine Kinase Enzyme Kinetics in Diabetic Cardiomyopathy. A 31P NMR Magnetization Transfer Study of the Intact Beating Rat Heart. Mol Cell Cardiol. 1999; 31: 2175-2189.10.1006/jmcc.1999.104410640445Search in Google Scholar

[27] Thulesen J, Orskov C, Holst JJ, Poulsen SS: Short Term Insulin Treatment Prevents the Diabetogenic Action of Streptozotocin in Rats. Endocrin. 1997; 138 (1): 62-67.10.1210/endo.138.1.48278977386Search in Google Scholar

[28] Yu X, Tesiram YA, Towner RA, Abbott A, Patterson E, Huang1S, Garrett MW, Chandrasekaran S, Matsuzaki S, Szweda LI, Gordon BE, Kem1 DC. Early myocardial dysfunction in streptozotocin-induced diabetic mice: a study using in vivo magnetic resonance imaging (MRI). Cardiovascular Diabetology. 2007; 6:6 -10. 10.1186/1475-2840-6-6180542517309798Search in Google Scholar